Company Description
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally.
It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions.
The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools.
It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy.
The company distributes its products through independent distributors, direct salespeople, and patients.
The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
| Country | United States |
| Founded | 1995 |
| IPO Date | May 8, 2008 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 7,802 |
| CEO | Damien McDonald |
Contact Details
Address: 2711 Centerville Road, Suite 400 Wilmington, Delaware 19808 United States | |
| Phone | 302 252 9160 |
| Website | enovis.com |
Stock Details
| Ticker Symbol | ENOV |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001420800 |
| CUSIP Number | 194014502 |
| ISIN Number | US1940145022 |
| Employer ID | 54-1887631 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Damien McDonald | Chief Executive Officer and Director |
| Phillip Benjamin Berry | Senior Vice President and Chief Financial Officer |
| Bradley J. Tandy J.D. | Senior Vice President and Chief Legal Officer |
| Patricia A. Lang | Senior Vice President and Chief Human Resources Officer |
| Daniel A. Pryor | Advisor |
| John Kleckner | Vice President, Controller and Chief Accounting Officer |
| Oliver Engert | Chief Administrative Officer |
| Kyle William Rose | Vice President of Investor Relations |
| Katie Sweet | Vice President of Corporate Communication |
| Tim Czartoski | President of U.S. Surgical and Global Product and Enabling Technologies |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 26, 2026 | 10-K | Annual Report |
| Feb 26, 2026 | 8-K | Current Report |
| Jan 21, 2026 | SCHEDULE 13G/A | Filing |
| Jan 12, 2026 | 8-K | Current Report |
| Dec 15, 2025 | 8-K | Current Report |
| Dec 10, 2025 | 8-K | Current Report |
| Nov 14, 2025 | 8-K | Current Report |
| Nov 6, 2025 | 10-Q | Quarterly Report |
| Nov 6, 2025 | 8-K | Current Report |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |